Economic Assistance in Connection with Class Certification

For a blockbuster drug with an ongoing market presence, we analyzed the economic underpinnings of commonality and typicality arguments. We showed that causation and damages assessments could not reliably be based on common methods of proof for the entire class based on examination of a variety of factors (e.g., patient demographics, medical profiles, medical injury, drug usage). We relied extensively on third-party market research data (e.g., IMS, Scott-Levin, MMI) to develop these economic analyses.